09:25:48 EST Sun 25 Feb 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 178,356,426
Close 2023-01-11 C$ 0.68
Market Cap C$ 121,282,370
Recent Sedar Documents

Cybin selects GAD as target indication for CYB004

2023-01-12 09:53 ET - News Release

MR. Doug Drysdale reports

CYBIN SELECTS GENERALIZED ANXIETY DISORDER AS TARGET INDICATION FOR DEUTERATED DMT MOLECULE CYB004

Cybin Inc. has selected generalized anxiety disorder (GAD) with or without major depressive disorder (MDD) as the target indication for its proprietary deuterated N,N-dimethyltryptamine (DMT) molecule, CYB004.

"Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent," said Doug Drysdale, chief executive officer of Cybin. "Since the pandemic, the prevalence of depression and anxiety has been significantly elevated, and we are optimistic that, through our current development programs, Cybin has the potential to provide innovative therapeutics to alleviate the mental suffering that so many people experience worldwide. We remain focused on the opportunity that CYB004, as a new chemical entity, may be able to provide a new path toward mental healing."

Generalized anxiety disorder is characterized by excessive worry and tension that is not restricted to any specific environmental circumstances. Anxiety disorders are the most common mental health concern in the United States. Over 40 million adults in the U.S. (19.1 per cent of the total United States population) have an anxiety disorder.

Additional facts about anxiety and generalized anxiety disorder:

  • Among psychiatric disorders, GAD and MDD are the leading contributors to global disability. The presence of both GAD and MDD is strongly associated with a poor prognosis, an increase in severe symptoms, poorer quality of life, greater MDD recurrence and a higher suicide risk than either disorder alone.
  • GAD affects 6.8 million adults, or 3.1 per cent of the U.S. population, in any given year.
  • Women are twice as likely to be affected by GAD.
  • Worldwide, GAD affects 14.7 million people in any given year.
  • 23 per cent of adults prescribed an SSRI discontinued medication at four weeks and 36.5 per cent within three months. Another report indicated that approximately one-half of patients discontinued antidepressant medication within three months.
  • There is a lifetime morbidity risk for GAD, with around 9 per cent prevalence.
  • Based on a 2022 generalized anxiety disorder therapeutics market report, the economic burden of GAD is expected to grow to $12-billion (U.S.) by 2030.

About Cybin Inc.

Cybin is currently conducting a phase 1 exploratory trial (CYB004-E trial) evaluating IV N,N-dimethyltryptamine to yield essential safety and dosing optimization data for the future clinical development of CYB004 for the treatment of GAD. To date, the CYB004-E trial has not demonstrated any clinically significant safety or tolerability issues. Cybin expects to translate key learnings from the initial study cohorts, including dose optimization and dosing dynamics, to support the remaining planned cohorts in the trial. These learnings are also expected to accelerate Cybin's plans to commence dosing of CYB004 in humans.

In its natural form, DMT is rapidly metabolized in the body and is not orally bioavailable. Based on preclinical studies, CYB004 has the potential to overcome the limitations of DMT. Specifically, these data showed that CYB004 had increased oral and pulmonary bioavailability, faster onset with lower doses, low inter-subject variability, and better dose titration for potentially fewer side effects compared with oral and IV DMT.

Cybin secured a U.S. composition of matter patent covering CYB004 in February, 2022.

The company plans to provide an update on its CYB004 program by the end of February, 2023.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.